Pharma Deals Review, Vol 2007, No 87 (2007)

Font Size:  Small  Medium  Large

Merck & Co. Strengthens CV Pipeline with Selective Acquisition

Business Review Editor

Abstract


Merck & Co. has made a move to bolster its cardiovascular drug pipeline by investing US$350 M to acquire NovaCardia. The main asset in the NovaCardia acquisition is its Phase III acute congestive heart failure drug KW-3902.

Full Text: pdf

Add comment

Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.